Seres Therapeutics, Inc. MCRB
1.89 USD +0.06 (+3.28%)
Nov 3, 2026, 3:21 PM EST
1.85 Day range 1.97
1.68 52-week range 29.98
- YTD
- -87.30%
- 1 year
- -87.60%
News
benzinga.com Seres Therapeutics Announces Publication Of Results From Phase 1b Clinical Study Of SER-155 In Adults Undergoing Allogeneic Hematopoietic Cell Transplantation In Nature Medicine Issue Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placeboTranslational data…
globenewswire.com Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data…
benzinga.com On, October 22, 2026, Seres Therapeutics' CFO Marella Thorell Resigned Effective November 15, 2026 On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and…
benzinga.com Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026 Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tubeSER-428 significantly reduced…
globenewswire.com Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube
defenseworld.net Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report)'s share price crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.48 and traded…
defenseworld.net Seres Therapeutics (NASDAQ:MCRB) Share Price Breaks Below 50 Day Moving Average – Should You Sell? Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $4.73 and traded as low as…
defenseworld.net Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Seres Therapeutics (NASDAQ: MCRB - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
globenewswire.com Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4,…
globenewswire.com Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C.…
benzinga.com Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units SERES THERAPEUTICS, INC.$300,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to…
benzinga.com Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of…
globenewswire.com Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored…
marketbeat.com Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further…
benzinga.com Seres Therapeutics Posts Early Data for Cancer Therapy Complication Seres Therapeutics Inc. (NASDAQ:MCRB) on Wednesday reported topline results from an investigator-sponsored trial evaluating SER-155 in patients with immune-related enterocolitis (irEC), with most…
benzinga.com Seres Therapeutics Posts Early Data for Cancer Therapy Complication Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical response by Day 15.
seekingalpha.com Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
benzinga.com Seres Therapeutics Announces Top-Line Results From An IST Evaluating SER-155 In Patients With irEC; SER-155 Well Tolerated, With No Drug-Related Serious Adverse Events Observed The study (NCT06801067), conducted at MSK, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases, evaluated SER-155 in 15 patients with…
globenewswire.com Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment 80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan…- benzinga.com Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and…
globenewswire.com Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line…
benzinga.com This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.- benzinga.com HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12 HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.
benzinga.com Seres Therapeutics Announces Balance Sheet Transactions; Nestle To Pay Company $25 M In Two Installments To Buy Out Sales Milestone Payments Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected…
globenewswire.com Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones
globenewswire.com Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C.- benzinga.com Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the analyst consensus estimate of $(1.88) by 10.64 percent. This is a 155.47 percent decrease over…
globenewswire.com Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live…- benzinga.com Seres Therapeutics Presents New Preclinical Data To Support Design, Potential Of SER-603 Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced new preclinical data supporting the design and potential of SER-603, a…
- benzinga.com Seres Therapeutics Presents New Preclinical Data Supporting Design And Potential Of SER-603, Next-Gen Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease, At DDW 2026 Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based…
globenewswire.com Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based…- benzinga.com Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21 Presentations DetailsPoster Presentation (Abstract 1726)Title: Effect of investigational, live biotherapeutic, SER-155, on gastrointestinal (GI) microbiome composition in adults receiving allogeneic…
globenewswire.com Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
globenewswire.com Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
benzinga.com Earnings Scheduled For March 12, 2026 - benzinga.com Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.22) by 20.61 percent. This is a 10 percent decrease over losses of…
- benzinga.com Seres Therapeutics Appoints Richard N. Kender As Executive Chair And Interim CEO Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Richard N. Kender as Executive Chair and Interim Chief…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash Seres stock drops after pausing a key drug study and cutting 30% of staff. The company shifts focus to early-stage programs while seeking funding, extending cash runway into 2026.- benzinga.com Seres Therapeutics Finalizes Protocol For Phase 2 Study Of SER-155 In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With FDA Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup…
- benzinga.com Seres Therapeutics Publishes New Data In Nature Medicine And Journal Of Infectious Diseases Supporting VOWST Mechanism And Broader Live Biotherapeutics Platform Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patientsSeres MbTx® platform provides high-resolution functional biological understanding…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday